NCT03239691View on ClinicalTrials.gov

A Study to Evaluate the Effect of ACT-709478 in Photosensitive Epilepsy Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

October 6, 2017

Primary Completion Date

April 25, 2018

Study Completion Date

April 25, 2018

Conditions
Photosensitive Epilepsy
Interventions
DRUG

ACT-709478 for oral use

Hard gelatin capsules for oral administration formulated at strengths of 10 mg and 100 mg

DRUG

Placebo

Matching placebo available as matching capsules for oral administration

Trial Locations (5)

33617

Bethel Epilepsy Center, Mara Hospital, Bielefeld

60528

Epilepsy Center Frankfurt, Frankfurt

77694

Epilepsiezentrum Kork, Kehl

94275

HOSP - Bicêtre Neurologie, Le Kremlin-Bicêtre

01454

Kleinwachau, Sächsisches Epilepsiezentrum Radeberg, Radeberg

Sponsors
All Listed Sponsors
lead

Idorsia Pharmaceuticals Ltd.

INDUSTRY